Latest news
Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
Novartis Financial Results – Q1 2024
Novartis announced the company’s financial results for the first quarter of 2024.
Novartis in Society Integrated Report 2023
Learn about our business, strategy and performance in 2023, and how we create sustainable value for stakeholders and society.
Annual Report 2023
This report, filed with the SIX Swiss Exchange in Switzerland, provides a comprehensive overview of Novartis, including our company structure, corporate governance and compensation practices. It also contains our operating and financial results, accompanied by audited annual financial statements.
Humanitarian response
Violence against innocent people runs counter to our work to improve human health
Novartis condemns all acts of terrorism and violence. Our thoughts are with all those affected by the tragic events that continue to unfold in Israel, Gaza and the West Bank.
Novartis unwavering in support one year on from the start of the war in Ukraine
On February 24, we marked the first anniversary of the war in Ukraine. Novartis continues to condemn the ongoing conflict, while our unwavering support to those impacted continues through humanitarian aid, financial donations and critical medicines.